Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

India-Based Enzene Biosciences Establishes Hopewell, New Jersey, Manufacturing Operations

09/17/2025
India-based biotechnology company Enzene Biosciences, Ltd. has established operations in Hopewell, New Jersey. The $50 million project is expected to create up to 300 jobs.

The new 80,000-square-foot manufacturing facility located on the Princeton West Innovation Campus will make extensive use of the company’s modular EnzeneX™ 2.0 platform, a fully-connected continuous manufacturing™ (FCCM™) technology.

“Enzene Biosciences is thrilled to establish our manufacturing operations in New Jersey, as it allows us to extend our local manufacturing capabilities to our valued North American clients,” said Dr. Himanshu Gadgil, CEO of Enzene Biosciences. “We are excited to provide them with access to our cutting-edge continuous manufacturing platform, which enables streamlined and efficient production processes. New Jersey’s highly skilled workforce, state-of-the-art infrastructure, and renowned academic institutions make it an ideal location for Enzene, ensuring that we can deliver exceptional services and support to our clients in the U.S.”

As a Contract Development and Manufacturing Organization (CDMO), Enzene Biosciences, a subsidiary of Alkem Laboratories, Ltd., provides services to global pharmaceutical companies, partnering with them in their drug development and manufacturing processes.

“We are so proud to welcome Enzene to New Jersey’s thriving life sciences ecosystem,” noted Wesley Mathews, President and CEO of Choose New Jersey. “Yet another Indian biopharma company has established itself in the state, demonstrating the strength of the New Jersey-India economic partnership. Beyond economic and commercial ties, our academic and cultural connections make it the perfect fit for Indian companies looking to expand to North America. Enzene’s growth in this sector highlights New Jersey’s global presence throughout all areas of the biopharmaceutical industry — from clinical trials to large-scale manufacturing.”

“We are thrilled that Enzene Biosciences has chosen Princeton as the location for its new biomanufacturing facility – Enzene’s only U.S. site,” added Debbie Hart, BioNJ President and CEO. “With its extensive drug development know-how and experience, Enzene will be a valuable addition to New Jersey’s robust life sciences ecosystem – bringing innovative medicines to Patients around the world. A leading biomedical hub, the Garden State boasts a full complement of large and small biopharmaceutical companies, universities, research institutions, clinical research organizations, and service providers working together to make meaningful advances in healthcare.”

Exclusive Research